For the treatment of advanced NSCLC, EGFR TKIs (gefitinib, erlotinib, afatinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, and alectinib) have been approved in Europe and the United States [12]. Here, ALK is linked to non-small cell lung carcinoma.